Journal of Reports in Pharmaceutical Sciences
CYP2C9*1*2 and VKORC1-1639 AA Polymorphisms Correlation with Warfarin Dose Requirement: A Case Report
Zohreh Hoseinkhani1, Reza Khodarahmi1, Mona Sadeghalvad1, Fathemeh Norooznezhad1, Kamran Mansouri1,*Abstract
CYP2C9 and VKORC1-1639 G>A genes as the genetic factors significantly influence the warfarin dose requirement in individuals. The patients with genetic variations in CYP2C9 and VKORC1 are at increased risk of adverse warfarin-related events. A young patient with atrial septal defect being highly sensitive to normal daily dose of warfarin was subjected to the study. The patient consented to genetic testing. Furthermore, DNA was isolated and PCR-RFLP performed. The patient required low warfarin dose of 11 mg/week to achieve the target international normalized ratio (INR). Genetic testing revealed that the patient carried VKORC1-1639 AA and CYP2C9*1*2 genotypes. Our findings reaffirm the significance of pharmacogenetic analysis prior to the warfarin therapy to achieve an efficient treatment and the least side/adverse drug effects.
Copyright
© 2018, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
Khaleqsefat E, Khalaj-Kondori M, Jabarpour Bonyadi M, Soraya H, Askari B. The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm. Iran J Pharm Res. 2020;19(3):e124400. doi: https://doi.org/10.22037/ijpr.2020.1101116
Review of Warfarin; A Cytochrome P450 Metabolizing Drug, in Clinical Practice
Tolou-Ghamari Z, Mazdak H. Review of Warfarin; A Cytochrome P450 Metabolizing Drug, in Clinical Practice. Jentashapir J Cell Mol Biol. 2016;7(3):e32641. doi: https://doi.org/10.17795/jjhr-32641
Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
Rafiee S, Rajabibazl M, Meshkani R, Daraei A, Zargari M, et al. Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population. Iran J Pharm Res. 2017;16(3):e124969. doi: https://doi.org/10.22037/ijpr.2017.2095
Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients
Khosropanah S, Faraji SN, Habibi H, Yavarian M, Mansoori R, et al. Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients. Iran J Pharm Res. 2017;16(3):e124947. doi: https://doi.org/10.22037/ijpr.2017.2074
Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study
Makohusová M, Mrázová V, Bednárová A, Milatová E, Sokol J, et al. Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study. Iran J Pharm Res. 2019;18(2):e126239. doi: https://doi.org/10.22037/ijpr.2019.1100653
- Scopus by DOI: 0
Last Update: 1 month ago
- Scopus by Title: 1
Last Update: 1 month ago
- Scopus by Title (Ref): 0
Last Update: 1 month ago
- CrossRef: 0
Last Update: 5 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):